News

Lixisenatide (Lyxumia®)

The NCPE does not recommend reimbursement of lixisenatide for patients with type 2 diabetes mellitus at the submitted price.

Eltrombopag (Revolade®)

Apixaban (Eliquis®)

The NCPE believe that apixaban is cost effective for this indication

Pneumococcal Vaccination

Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland PCV13 is the most cost-effective option if the analysis is based on a serotype distribution reflecting 2011 data. download document

Oncotype DX®

Cost-effectiveness of Oncotype DX® to target chemotherapy use in lymph-node-negative, oestrogen-receptor-positive, early-stage breast cancer in Ireland.

Fingolimod (Gilenya®)

Following a price revision we now consider Fingolimod (Gilenya®) a cost-effective therapy for the treatment of relapsing-remitting multiple sclerosis patients in the Irish healthcare setting.

Rotavirus Vaccine

Cost effectiveness analysis of a universal infant rotavirus vaccination programme in Ireland

Colorectal Cancer Screening programme

Health Technology Assessment (HTA) of population-based colectoral cancer screening programme in Ireland.

Glucosamine sulfate (Dona®)

We do not believe that glucosamine sulfate (DONA®) is a cost effective therapy for the treatment of osteoarthritis in the Irish Healthcare setting.

Melatonin (Circadin®)

We believe that there is currently insufficient evidence to support the reimbursement of this product under the Community Drugs Schemes.